Anti-infective Agents : Antiviral Agents
OTAMI1 “Tamiflu capsule” 75 mg/cap
適應症：成人和1歲以上兒童的流行感冒之預防及治療。
Usual dose:
Avian influenza
Adult:
75 mg orally twice daily for 5 days; higher doses (150 mg twice daily) and longer duration of therapy (up to 10 days) may be considered on a case-by-case basis (pneumonia or progressive disease).
Pediatric:
children older than 1 year and weighing 15 kg or less, 30 mg orally twice daily for 5 days.
children weighing more than 15 to 23 kg, 45 mg orally twice daily for 5 days.
children weighing more than 23 to 40 kg, 60 mg orally twice daily for 5 days.
children weighing more than 40 kg, 75 mg orally twice daily for 5 days.
Influenza, Virus types A and B
Adult:
75 mg orally twice daily for 5 days (manufacturer dose). May consider longer duration in patients who remain severely ill after 5 days of treatment (guideline dose).
Pediatric:
Full-term infants from birth to 1 year: 3 mg/kg orally twice daily for 5 days; data are insufficient to recommend a specific dose for premature infants (guideline dose).
Aged 2 weeks to younger than 1 year, 3 mg/kg/dose orally twice daily for 5 days (manufacturer dose). May consider longer duration in patients who remain severely ill after 5 days of treatment (guideline dose).
Aged 1 year or older and 15 kg or less, 30 mg orally twice daily for 5 days (manufacturer dose). May consider longer duration in patients who remain severely ill after 5 days of treatment (guideline dose).
Aged 1 year or older and greater than 15 to 23 kg, 45 mg ORALLY twice daily for 5 days (manufacturer dose). May consider longer duration in patients who remain severely ill after 5 days of treatment (guideline dose).
Aged 1 year or older and greater than 23 to 40 kg, 60 mg ORALLY twice daily for 5 days (manufacturer dose). May consider longer duration in patients who remain severely ill after 5 days of treatment (guideline dose).
Aged 1 year or older and greater than 40 kg, 75 mg orally twice daily for 5 days (manufacturer dose). May consider longer duration in patients who remain severely ill after 5 days of treatment (guideline dose)
Adverse effect:
Common: nausea, vomiting, headache.
Serious: cardiac dysrhythmia, erythema multiforme, facial swelling, Stevens-Johnson syndrome, toxic epidermal necrolysis, gastrointestinal hemorrhage, hemorrhagic colitis, hepatitis, anaphylaxis, seizure, abnormal behavior, delirium.